Magen Biosciences Licenses Dermatology Assets from Eli Lilly and Company

Magen Biosciences Licenses Dermatology Assets from Eli Lilly and Company

WALTHAM, Mass. -- Magen BioSciences, Inc., a privately held specialty pharmaceutical company focused on developing pharmaceuticals to treat diseases of the skin, announced today that it had acquired the rights to a series of novel pre-clinical compounds from Eli Lilly and Company (NYSE: LLY). Under the terms of the agreement, Magen has been granted the exclusive worldwide rights to develop and commercialize products based on these compounds for all dermatology applications. Other terms of the deal were not disclosed.

“This transaction marks a significant milestone in the growth of Magen to become a premier, science-based dermatology company,” said Brian M. Gallagher, Ph.D., President and CEO. “We will leverage the prior research done by Lilly's scientists, and will dedicate our efforts to continue to advance these assets through the development process.”

The licensed compounds have shown anti-inflammatory, and anti-proliferative activities in several preclinical models. These properties suggest a number of possible applications to treat common dermatological disorders.

About Magen BioSciences

Magen BioSciences was founded in 2006 by an outstanding group of scientists and investors to build a science-based dermatology company. The company is a research and development stage enterprise that acquires and develops novel and proprietary technologies and is headquartered in Waltham, Massachusetts.

Suggested Articles

Bluebird Bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.